Tysoe O
Nat Rev Endocrinol. 2023;19(3):129.
The TriMaster trial is investigating the possibility of precision medicine for people with type 2 diabetes, and how this translates to improve outcome. Results suggest both weight and renal function could be useful tools to guide treatment choices, but also that patient preference affects outcomes.
Just published
In collaboration with
May
2023
